Dr. Gralow Discusses the Antibody Drug Conjugate T-DM1

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, Discusses the Antibody Drug Conjugate T-DM1 for Breast Cancer.

Julie R. Gralow, MD, Director, Breast Medical Oncology, Seattle Cancer Care Alliance (SCCA), discusses the antibody-drug conjugate T-DM1 that covalently links the monoclonal antibody trastuzumab with the cytotoxic drug emtansine (DM1) for patients with HER2-positive metastatic breast cancer.

Gralow describes T-DM1 as a very smart and exciting new drug that is able to deliver chemotherapy effectively with minimal side effects, since the bulk of the chemotherapy is delivered directly to the cancer cell. The positive data from the phase III EMILIA trial acts as a proof of principle not only for T-DM1 but also for antibody drug conjugates as a whole.

Gralow is very excited about the concept of antibody drug conjugates — specifically the efficacy of T-DM1 in patients with HER2-positive breast cancer.

Related Videos
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,